Cimalgex 8mg Chewable Tablets for Dogs

Dogs:
Very common
(>1 animal / 10
animals treated):
Vomiting
, Diarrhoea
Rare
(1 to 10 animals /
10,000 animals
treated):
Digestive tract haemorrhage
, Gastric ulceration
,
Anorexia, Lethargy, Polyuria, Polydipsia
Very rare
(<1 animal / 10,000
animals treated,
including isolated
reports):
Elevated renal parameters, Renal failure
1
Mild and transient gastro-intestinal disorders
Serious gastro-intestinal disorders
Kidney function should be monitored during long-term NSAID treatment.
If any observed adverse effect persists after stopping treatment, the advice of a
veterinarian should be sought.
If adverse reactions such as persistent vomiting, repeated diarrhoea, faecal
occult blood, sudden weight loss, anorexia, lethargy or worsening of renal
or hepatic biochemistry parameters occur, use of the product should be
discontinued and appropriate monitoring and/or treatment should be put in
place. As with other NSAIDs, serious adverse effects can occur and, in rare
cases, may be fatal
Reporting adverse events is important. It allows continuous safety
monitoring of a veterinary medicinal product. Reports should be sent,
preferably via a veterinarian, to either the marketing authorisation holder or
the national competent authority via the national reporting system. See the
package leaflet for respective contact details.